Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Arthrospira maxima
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Inner Ear Support' Oral Capsule in Patients with Sudden Sensorineural Hearing Loss
Details : Arthrospira maxima is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hearing Loss, Sensorineural.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 30, 2025
Lead Product(s) : Arthrospira maxima
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Multicomponent Dietary Supplement
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Recipient : Shih Chien Huang
Deal Size : Inapplicable
Deal Type : Inapplicable
Dietary Supplementation on Tear Secretion and Inflammation in DES
Details : Multicomponent Dietary Supplement is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : Multicomponent Dietary Supplement
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Recipient : Shih Chien Huang
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FB-1603
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FB-1603 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 27, 2024
Lead Product(s) : FB-1603
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : National Taiwan University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Spirulina
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Taipei Medical University WanFang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Spirulina (FEM-102) Supplement to Chronic Hepatitis B Patients
Details : Spirulina is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : Spirulina
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Taipei Medical University WanFang Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apomivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Investigate the Efficacy and Safety of Apomivir®
Details : Apomivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 03, 2012
Lead Product(s) : Apomivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
